Tempero secures $70M to fund study duo for addiction candidate

Tempero Bio Raises $70M for Addiction Treatment Research

Tempero Bio, an Oakland-based biotechnology company, has secured $70 million in Series B funding15.

The funding will support two Phase 2 clinical trials for TMP-301, their lead drug candidate targeting substance use disorders15.

TMP-301 is a metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator (NAM) designed to address the neurobiological basis of addiction5.

The clinical trials will focus on alcohol use disorder and cocaine use disorder5.

The funding round was led by 8VC, with participation from Aditum Bio, Khosla Ventures, and other investors5.

Tempero Bio was established in 2020 through a collaboration between Aditum Bio and Soshei Heptares (now Nxera Pharma)1.

The company aims to address the urgent need for more effective treatments for substance use disorders, which affect 48 million Americans and contribute to over 100,000 deaths annually5.

TMP-301 has shown promising results in preclinical studies for alcohol, cocaine, and opiate use disorders5.

The drug has been evaluated in over 80 healthy volunteers in Phase 1 trials, demonstrating an acceptable safety and tolerability profile5.

Tempero Bio plans to use the funding for Phase 3-enabling activities and preclinical studies for additional indications and formulations5.

Sources:

1. https://www.biopharmadive.com/news/tempero-bio-substance-abuse-series-b-funding/743305/

5. https://pulse2.com/tempero-bio-70-million-series-b-closed-to-advance-tmp-301-into-phase-2-trials-for-substance-use-disorders/